Reviewing the rising price of EpiPens :  hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fourteenth Congress, second session, September 21, 2016. 

 - iii, 95 pages ;  24 cm 
<br/><br/> Shipping list no.: 2017-0115-M.  Paper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  "Serial no. 114-124."  CRDP Program record. 
<br/><br/>Includes bibliographical references. 
<br/><br/><br/>Microfiche. <br/>[Washington, D.C.] : <br/>U.S. Government Printing Office, <br/>[2017] <br/>2 microfiches : negative. 
<br/><br/><label>Subjects--Corporate Names: </label><br/>Mylan, Inc--Corrupt practices.
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenaline--Prices--United States.<br/>Drug delivery devices--Prices--United States.
<br/><br/><label>Index Terms--Genre/Form: </label><br/>Legislative hearings.
<br/><br/><label>LC Class. No.: </label>KF27  / .O94 2016 
<br/><br/><label>GPO Item No.: </label>1016-B (MF) 
<br/><br/><label>Gov. Doc. Class. No.: </label>Y 4.G 74/7:114-124 
<br/><br/><label>Report. No.: </label>Serial no. 114-124 (United States. Congress. House. Committee on Oversight and Government Reform)